This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
J.Jill (JILL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
JILLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Amicus (FOLD) Gets FDA Approval for Pompe Disease Drug
by Zacks Equity Research
Amicus (FOLD) receives approval for Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) from the FDA to treat the adult late-onset Pompe disease.
FOLDNegative Net Change CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change
biotechnology medical
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
AZNNegative Net Change PFENegative Net Change MRNANegative Net Change
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
3D Systems (DDD) to Expand VSP Bolus Distribution With Klarity
by Zacks Equity Research
3D Systems' (DDD) collaboration with Klarity is likely to help it in expanding the distribution of its FDA-approved VSP Bolus solution.
NVDAPositive Net Change UTHRNegative Net Change DDDPositive Net Change ASURNegative Net Change
biotechnology computers oncology-screening tech-stocks
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent
by Zacks Equity Research
Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils.
DVAXNegative Net Change CORTNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
by Zacks Equity Research
Acquisition news from Intercept (ICPT) and study updates from Immunovant (IMVT) are in focus in the biotech sector.
ICPTPositive Net Change IONSNegative Net Change SLNONegative Net Change IMVTNegative Net Change PLRXPositive Net Change
biotechnology biotechs
Should You Buy MillerKnoll (MLKN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MLKNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
by Zacks Equity Research
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
LLYNegative Net Change NKTRPositive Net Change ANIKNegative Net Change ANVSNegative Net Change
biotechnology medical
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
by Zacks Equity Research
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
CORTNegative Net Change ANIKNegative Net Change BHVNNegative Net Change ANVSNegative Net Change
biotechnology medical
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
by Zacks Equity Research
Pliant's (PLRX) phase II study on lead pipeline candidate bexotegrast, achieves its primary and secondary endpoints. Shares rise
NVSNegative Net Change DVAXNegative Net Change ETONNegative Net Change PLRXPositive Net Change
biotechnology biotechs pharmaceuticals
5 Best Leveraged-Inverse ETFs of September
by Sweta Killa
September is on track to be the worst month of the year.
LABDPositive Net Change DRVPositive Net Change HIBSPositive Net Change MSOXPositive Net Change JETDPositive Net Change
airlines biotechnology etfs marijuana real-estate
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
by Zacks Equity Research
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
NVSNegative Net Change BIIBNegative Net Change ICPTPositive Net Change ETONNegative Net Change
biotechnology biotechs
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
by Zacks Equity Research
Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.
DVAXNegative Net Change CORTNegative Net Change IMVTNegative Net Change ROIVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
by Zacks Equity Research
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
CORTNegative Net Change ANIKNegative Net Change SLNONegative Net Change ANVSNegative Net Change
biotechnology medical
Repligen (RGEN) to Acquire Fluid Management Company Metenova
by Zacks Equity Research
Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.
RGENNegative Net Change CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change
biotechnology medical
Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down
by Zacks Equity Research
Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.
DVAXNegative Net Change AMGNNegative Net Change CHRSNegative Net Change ETONNegative Net Change
biotechnology biotechs pharmaceuticals
Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs
by Zacks Equity Research
Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.
DVAXNegative Net Change NVONegative Net Change CORTNegative Net Change BTTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
by Zacks Equity Research
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
CORTNegative Net Change ANIKNegative Net Change ANVSNegative Net Change
biotechnology medical
Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study
by Zacks Equity Research
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
NVSNegative Net Change DVAXNegative Net Change ETONNegative Net Change
biotechnology pharmaceuticals
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
DVAXNegative Net Change MRKNegative Net Change SGENPositive Net Change CORTNegative Net Change
biotechnology biotechs cell-therapy immuno-therapy medical pharmaceuticals
CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns
by Zacks Equity Research
Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.
SNYNegative Net Change AZNNegative Net Change GSKNegative Net Change PFENegative Net Change
biotechnology medical
The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management
by Zacks Equity Research
Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.
BANegative Net Change AMZNNegative Net Change REGNNegative Net Change BSXNegative Net Change WMNegative Net Change
aerospace biotechnology business-services medical retail
Company News for Sep 25, 2023
by Zacks Equity Research
Companies In The News Are: F, ATVI, MSFT, SGEN, SCHL.
FPositive Net Change MSFTNegative Net Change ATVINegative Net Change SGENPositive Net Change SCHLPositive Net Change
auto-tires-trucks biotechnology consumer-discretionary tech-stocks
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
BANegative Net Change AMZNNegative Net Change REGNNegative Net Change BSXNegative Net Change MONegative Net Change WMNegative Net Change
aerospace biotechnology pharmaceuticals retail
Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.
BMYNegative Net Change DVAXNegative Net Change MRKNegative Net Change ETONNegative Net Change
biotechnology biotechs